Non-keratinising nasopharyngeal carcinoma
Conditions
Interventions
Induction chemoimmunotherapy group for stages III-IV:None
Patients with nasopharyngeal carcinoma in stages I and II:None
Induction chemotherapy group for stages III-IV:None
Sponsors
The First Affiliated Hospital of Xiamen University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Gender is not limited, age 18-70 years old; 2. Nasopharyngeal non-keratinizing carcinoma (WHO type II or III) confirmed by pathological tissue; 3. Clinical stage is stage I-IVa (AJCC/UICC 8th edition), no evidence of distant metastasis; 4. ECOG score 0-1 points; 5. No previous anti-tumor treatment such as radiotherapy, chemotherapy, immunotherapy or biological therapy for nasopharyngeal cancer; 6. No contraindications to radiotherapy and chemotherapy; 7. The functional level of major organs meets the following standards: 1) Blood routine examination standards must be met: WBC>=4.0×10^9/L, ANC>=1.5×10^9/L, PLT>=100×10^9/L, HGB>=90g/L (no blood transfusion or blood products within 14 days, no correction with G-CSF and other hematopoietic stimulating factors); 2) Biochemical examination should meet the following criteria: ALT, AST=60ml/min (Cockcroft-Gault formula); 8. Subjects voluntarily join this study, sign the informed consent form, have good compliance, and cooperate with follow-up;
Exclusion criteria
Exclusion criteria: 1.Keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma; 2.Previous or concurrent diagnosis of other uncured malignancies (except cured basal cell carcinoma of the skin, cervical carcinoma in situ, and superficial bladder cancer). 3.Currently enrolled in another interventional clinical trial; 4.Women who are pregnant or breastfeeding; 5.Uncontrolled Cardiovascular Disease:Myocardial ischemia (>= Grade II) or myocardial infarction; Poorly controlled arrhythmias (including QTc interval >=470 ms); Cardiac dysfunction (NYHA Class III-IV) or left ventricular ejection fraction (LVEF) <50% by echocardiography; Myocardial infarction within the past year. 6.Other Severe Comorbidities:Uncontrolled hypertension; Severe cerebrovascular disease; Severe renal disease; Uncontrolled diabetes mellitus; Other chronic debilitating diseases. 7.History of drug/alcohol addiction; Psychiatric disorders; Lack of legal capacity or limited legal capacity. 8.Any familial or social circumstances that, in the investigator’s judgment, may compromise subject safety or data collection, leading to premature study termination;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival;Overall survival;Treatment response;SUV; | — |
Countries
China
Contacts
Public ContactQin Lin
The First Affiliated Hospital of Xiamen University
Outcome results
None listed